Clinical trials: Glucocorticoids
Glucocorticoid-Refractory aGVHD
A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)
This is an open-label,single arm,Phase Ib study,in order to evaluate the safety,tolerability, preliminary efficacy and pharmacokinetics of TQ05105 tablets in subjects with Glucocorticoid-Refractory aGVHD
- Trial name
- NCT04941404
- Testing
- TQ05105 tablets
- Where
- 4 sites in China
- Volunteers
- 13 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Glucocorticoid-induced Osteoporosis
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
The main objective of this study is to evaluate the efficacy of Prolia® in improving bone mass density (BMD) of lumbar spine at month 12.
- Trial name
- NCT06588153
- Testing
- Prolia®
- Where
- 16 sites in China
- Volunteers
- 102 people
- Sponsor
- Amgen
Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With, Glucocorticoid-induced Osteoporosis
Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
To evaluate the effect of denosumab on lumbar spine bone mineral density (BMD) Z-score as assessed by dual-energy X-ray absorptiometry (DXA) at 12 months in children 5 to 17 year of age with Glucocorticoid (GC)-induced…
- Trial name
- NCT03164928
- Testing
- Denosumab
- Where
- 38 sites in United States, Australia and 11 more
- Volunteers
- 24 people
- Sponsor
- Amgen
Glucocorticoids Toxicity, COVID-19
Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects
The goal of this interventional study is to evaluate the pharmacokinetics, safety, and tolerability of 101-PGC-005 in healthy, adult, human subjects.
- Conditions
- Glucocorticoids Toxicity, COVID-19, Infectious Disease, Virus Diseases
- Trial name
- NCT05619770
- Testing
- 101-PGC-005
- Where
- India
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- 101 Therapeutics
Glucocorticoid Induced Osteoporosis
Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis
This is a randomized, double-blind, double-dummy, positive-controlled phase II interventional study designed to evaluate the efficacy and safety of JMT103 in the treatment of glucocorticoid induced osteoporosis patients.
- Trial name
- NCT05397938
- Testing
- JMT103, Alendronate sodium
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Shanghai JMT-Bio Inc.
Mild Cognitive Impairment (MCI)
Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health
Alzheimer disease (AD) is a dementing illness characterized by progressive neuronal degeneration, gliosis, and the accumulation of intracellular inclusions and extracellular deposits of amyloid in discrete regions of the basal…
- Trial name
- NCT03448055
- Testing
- Immunocal
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Immunotec Inc.
Relationship Between the Exposure of Glucocorticoids During Pregnancy and Orofacial Cleft Development
A Study to Learn More About the Relationship Between the Development of a Gap in the Upper Lip (Cleft Lip) or in the Roof of the Mouth (Cleft Palate) in Newborns and the Use of Glucocorticoids by the Mother During Pregnancy: a Meta-analysis
Glucocorticoids are drugs that have many effects on body metabolism, raise sugar level in the blood, and reduce inflammation. By applying a statistical technique for combining the findings from a systematic literature review…
- Trial name
- NCT03788863
- Testing
- Diflucortolone valerate (BAY866146)
- Where
- Germany
- Volunteers
- 99,999 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids
This is a 2-year study to evaluate the effect of denosumab versus risedronate in adults with glucocorticoid-induced osteoporosis.
- Trial name
- GIOP (NCT01575873)
- Testing
- Denosumab, Risendronate
- Where
- 99 sites in United States, Argentina and 14 more
- Volunteers
- 795 people
- Sponsor
- Amgen